BlackRock Health Sciences Opps Inv C
Fund
SHSCX
Price as of:
$53.47
- $0.41
- 0.76%
Primary Theme
fund company
Name
Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
Vitals
YTD Return
-2.0%
1 yr return
-9.0%
3 Yr Avg Return
-2.0%
5 Yr Avg Return
3.0%
Net Assets
$9.49 B
Holdings in Top 10
41.5%
52 WEEK LOW AND HIGH
$53.9
$48.51
$62.41
Expenses
OPERATING FEES
Expense Ratio 1.84%
SALES FEES
Front Load N/A
Deferred Load 1.00%
TRADING FEES
Turnover 19.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
$1,000
IRA
N/A
Fund Classification
Fund Type
Open End Mutual Fund
Name
Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
SHSCX - Profile
Distributions
- YTD Total Return -2.0%
- 3 Yr Annualized Total Return -2.0%
- 5 Yr Annualized Total Return 3.0%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -0.77%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annually
Fund Details
-
Legal NameBlackRock Health Sciences Opportunities Portfolio
-
Fund Family NameBlackRock
-
Inception DateOct 16, 2000
-
Shares OutstandingN/A
-
Share ClassC
-
CurrencyUSD
-
Domiciled CountryUnited States
-
ManagerErin Xie
Fund Description
Under normal market conditions, the Fund invests at least 80% of its total assets in equity securities, primarily common stock, of companies in health sciences and related industries. The health sciences sector can include companies in health care equipment and supplies, health care providers and services, biotechnology, and
pharmaceuticals. Health sciences and related industries can include, but are not limited to, businesses involved in the development, production, and distribution or delivery of medical and pharmaceutical products and services, companies engaged in biotechnology and medical research and development, companies that may design, manufacture or distribute medical, dental and optical equipment and supplies, including diagnostic equipment, and companies that may also provide diagnostic services or operate health facilities and hospitals, or provide related administrative, management and financial support. The Fund will concentrate its investments (i.e., invest more than 25% of its assets) in health sciences or related industries, and may invest in companies located in non-U.S. countries.
The Fund reserves the right to invest up to 20% of its total assets in other types of securities. These may include stocks of companies not associated with health sciences.
SHSCX - Performance
Return Ranking - Trailing
| Period | SHSCX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -2.0% | -25.6% | 24.5% | 73.18% |
| 1 Yr | -9.0% | -28.9% | 21.2% | 83.13% |
| 3 Yr | -2.0%* | -19.8% | 19.7% | 56.49% |
| 5 Yr | 3.0%* | -13.5% | 15.3% | 46.62% |
| 10 Yr | 5.3%* | -6.0% | 16.6% | 52.83% |
* Annualized
Return Ranking - Calendar
| Period | SHSCX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2022 | -14.4% | -53.9% | 11.7% | 69.09% |
| 2021 | 0.3% | -22.3% | 18.5% | 52.15% |
| 2020 | 4.3% | -4.7% | 41.4% | 55.84% |
| 2019 | 4.5% | -10.2% | 13.1% | 65.22% |
| 2018 | -0.2% | -5.7% | 26.9% | 29.55% |
Total Return Ranking - Trailing
| Period | SHSCX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -2.0% | -41.2% | 24.5% | 73.74% |
| 1 Yr | -9.0% | -28.9% | 28.3% | 83.62% |
| 3 Yr | -2.0%* | -19.8% | 19.7% | 57.67% |
| 5 Yr | 3.0%* | -13.5% | 15.3% | 49.30% |
| 10 Yr | 5.3%* | -6.0% | 16.6% | 65.42% |
* Annualized
Total Return Ranking - Calendar
| Period | SHSCX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2022 | -14.4% | -53.9% | 11.7% | 69.09% |
| 2021 | 0.3% | -22.3% | 18.5% | 52.15% |
| 2020 | 4.3% | -4.7% | 41.4% | 55.84% |
| 2019 | 4.5% | -10.2% | 13.1% | 65.94% |
| 2018 | -0.2% | -5.7% | 26.9% | 36.36% |
NAV & Total Return History
SHSCX - Holdings
Concentration Analysis
| SHSCX | Category Low | Category High | SHSCX % Rank | |
|---|---|---|---|---|
| Net Assets | 9.49 B | 732 K | 46.2 B | 5.85% |
| Number of Holdings | 150 | 3 | 507 | 12.18% |
| Net Assets in Top 10 | 4.17 B | 2.18 K | 21.6 B | 6.60% |
| Weighting of Top 10 | 41.45% | 12.3% | 100.0% | 61.93% |
Top 10 Holdings
- UnitedHealth Group Inc 9.44%
- Johnson & Johnson 4.46%
- Eli Lilly and Co 4.02%
- Thermo Fisher Scientific Inc 3.94%
- Pfizer Inc 3.79%
- Abbott Laboratories 3.45%
- AbbVie Inc 3.26%
- Cigna Corp 3.09%
- Danaher Corp 3.05%
- Medtronic PLC 2.98%
Asset Allocation
| Weighting | Return Low | Return High | SHSCX % Rank | |
|---|---|---|---|---|
| Stocks | 96.90% | 0.09% | 106.13% | 79.19% |
| Cash | 2.30% | -0.10% | 99.91% | 23.86% |
| Other | 0.80% | -22.99% | 3.38% | 15.74% |
| Preferred Stocks | 0.00% | 0.00% | 7.86% | 26.90% |
| Convertible Bonds | 0.00% | 0.00% | 0.37% | 28.43% |
| Bonds | 0.00% | 0.00% | 12.39% | 24.87% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | SHSCX % Rank | |
|---|---|---|---|---|
| Healthcare | 98.96% | 26.56% | 100.00% | 74.11% |
| Basic Materials | 0.73% | 0.00% | 14.83% | 15.23% |
| Financial Services | 0.31% | 0.00% | 8.43% | 8.63% |
| Utilities | 0.00% | 0.00% | 1.52% | 22.84% |
| Technology | 0.00% | 0.00% | 28.70% | 29.95% |
| Real Estate | 0.00% | 0.00% | 7.13% | 28.43% |
| Industrials | 0.00% | 0.00% | 7.02% | 27.92% |
| Energy | 0.00% | 0.00% | 0.00% | 22.34% |
| Communication Services | 0.00% | 0.00% | 12.28% | 26.90% |
| Consumer Defense | 0.00% | 0.00% | 25.73% | 31.98% |
| Consumer Cyclical | 0.00% | 0.00% | 14.20% | 27.92% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | SHSCX % Rank | |
|---|---|---|---|---|
| US | 90.61% | 0.09% | 104.41% | 26.40% |
| Non US | 6.29% | 0.00% | 45.40% | 80.20% |
SHSCX - Expenses
Operational Fees
| SHSCX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 1.84% | 0.08% | 3.13% | 8.54% |
| Management Fee | 0.67% | 0.00% | 1.25% | 56.38% |
| 12b-1 Fee | 1.00% | 0.00% | 1.00% | 81.61% |
| Administrative Fee | 0.07% | 0.03% | 0.25% | 18.42% |
Sales Fees
| SHSCX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 0.00% | 5.75% | N/A |
| Deferred Load | 1.00% | 1.00% | 5.00% | 57.14% |
Trading Fees
| SHSCX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| SHSCX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 19.00% | 0.00% | 238.00% | 18.67% |
SHSCX - Distributions
Dividend Yield Analysis
| SHSCX | Category Low | Category High | SHSCX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 2.44% | 40.10% |
Dividend Distribution Analysis
| SHSCX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annually | Annually | Monthly | Semi-Annually |
Net Income Ratio Analysis
| SHSCX | Category Low | Category High | SHSCX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.77% | -2.54% | 1.92% | 84.48% |
Capital Gain Distribution Analysis
| SHSCX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
SHSCX - Fund Manager Analysis
Managers
Erin Xie
Start Date
Tenure
Tenure Rank
Jul 31, 2003
18.85
18.9%
Ms. Xie is the managing director and Portfolio Manager of BlackRock Advisor since 2006. Before becoming part of BlackRock Advisors in 2005, she was with State Street Research & Management since 2001. Ms. Xie began her investment career as a pharmaceutical analyst for Sanford Bernstein in 1999.
Xiang Liu
Start Date
Tenure
Tenure Rank
Jun 01, 2020
2.0
2.0%
Director of BlackRock since 2016. Prior to joining BlackRock in 2008, Mr. Liu was a Partner and Biotech Analyst at Mehta Partners. Mr. Liu began his investment career in 2000 and has a BS from the University of Science & Technology (China), an MBA from the University of Chicago and a PhD degree in Chemistry from Yale University.
Jeff Lee
Start Date
Tenure
Tenure Rank
Jun 01, 2020
2.0
2.0%
Director of BlackRock since 2011. Mr. Lee began his investment career in 2006 and has a BA from Princeton University
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 24.72 | 7.17 | 2.12 |